Skip to main content
;

HESA Committee Report

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

PDF

APPENDIX A: LIST OF WITNESSES

 

The following table lists the witnesses who appeared before the Committee at its meetings related to this report. Transcripts of all public meetings related to this report are available on the Committee’s webpage for this study.

Organizations and Individuals

Date

Meeting

Amyotrophic Lateral Sclerosis Society of Canada

Tammy Moore, Chief Executive Officer

2018/09/27

112

Canadian Organization for Rare Disorders

Maureen Smith, Board Secretary

Durhane Wong-Rieger, President and Chief Executive Officer

2018/09/27

112

Department of Health

Catherine Parker, Director General, Biologics and Genetic Therapies Directorate, Health Products and Food Branch

Karen Reynolds, Executive Director, Office of Pharmaceuticals Management Strategies

John Patrick Stewart, Director General, Therapeutic Products Directorate

2018/09/27

112

As individuals

Craig Campbell, MD, Department Pediatrics and Neurology, Children's Hospital London Health Sciences Centre

Doug Coyle, Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa

Julian Midgley, Paediatric Nephrologist

2018/10/04

114

The Isaac Foundation

Andrew McFadyen, Executive Director

2018/10/04

114

As individuals

Michael Brudno, Professor and Scientific Director, Centre for Computational Medicine, Hospital for Sick Children

Joel Lexchin, Professor Emeritus, School of Health Policy and Management, York University

Ian Stedman, Osgoode Hall Law School, York University

2018/10/25

118

Children's Hospital of Eastern Ontario (CHEO)

Alex MacKenzie, Clinician Scientist

2018/10/25

118

Janssen Inc. Pharmaceutical Companies of Johnson & Johnson

Jacqueline Dobson, Government Affairs and Policy Manager, Government Affairs and Market Access

Stacey Silverberg, Stakeholder Engagement Manager, Government Affairs and Market Access

2018/10/25

118

Atypical Hemolytic Uremic Syndrome Canada

Mary Jane Vowles, Board Member

Caryn Vowles, Board Member

2018/10/30

119

Department of Health

Catherine Parker, Director General, Biologics and Genetic Therapies Directorate, Health Products and Food Branch

Karen Reynolds, Executive Director, Office of Pharmaceuticals Management Strategies

John Patrick Stewart, Director General, Therapeutic Products Directorate

2018/10/30

119

Liv-A-Little Foundation

Erin Little, President

2018/10/30

119

Canadian Agency for Drugs and Technologies in Health

Heather Logan, Acting Vice-President, Pharmaceutical Reviews

2018/11/06

121

Patented Medicine Prices Review Board

Douglas Clark, Executive Director

2018/11/06

121